uniQure (NASDAQ:QURE) Stock, Quote.Headers.trade-ideas

uniQure

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

Display,Of,Stock,Market,Quotes

News

Intraday Update

Markets

Movers

Trading Ideas

BEAM

CLSK

ERAS

MVST

NTLA

PCRX

QURE

RCKT

REPL

VERV

Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday

Section,Of,A,Financial,Newspaper,Titled,Key,Movers

CAPR

CLPT

DLTR

GPCR

IIIN

VBNK

uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday

Genome,Research.,Paternity,Confirmation.,Science,And,Medicine,Health,Care.,Determining

Biotech

Health Care

General

uniQure&#39;s AMT-130 receives FDA Breakthrough Therapy designation for Huntington&#39;s disease, adding to Fast Track, RMAT, and Orphan Drug statuses.

Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday?

uniQure NV

Press Releases

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

Small Cap

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

Earnings

uniQure Announces 2024 Financial Results and  Highlights Recent Company Progress

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease

uniQure to Announce First Quarter 2025 Financial Results

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

Management

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)

uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

uniQure Announces Appointment of Kylie O'Keefe  as Chief Customer and Strategy Officer

Comments

uniQure

uniQure (NASDAQ:QURE) Stock, Quote.Headers.trade-ideas

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell